Cardiac Opportunity Agent

An AI agent that reads the India Cardiac prescription audit, fuses it with a cited corpus of external signals, and ranks the opportunity spaces where Cipla has a clear and sustainable right to win over the next three to five years.

Built for Ascend Season 4 (2026), case study AI-Enabled Prioritization with Integrated Trend Analytics.


The one design decision that matters

The language model never calculates a number.

Every figure comes from a deterministic analytics engine written in ordinary Python. The model plans, selects tools, and writes prose about a finished evidence pack. Before any answer is released, a verifier extracts every number from the draft and checks it against that pack. Anything it cannot trace is rejected and the answer is rewritten.

That separation is what makes the output auditable. Re-run the engine on the same workbook and you get the same scorecard, byte for byte, whether or not a model was involved. It also means the system answers correctly with no API key at all, because the numbers were never the model’s job.


What it found

Cipla holds 1.68 per cent of a ₹23,244 crore market and grows at 4.6 per cent against the market’s 13.3 per cent. It ranks nineteenth of 279 companies. Two configurations inside that market are winnable, and both sit next to brands Cipla already owns.

Opportunity against right to win

The chart is the whole argument in one view. The vertical axis rates a space for anybody. The horizontal axis asks whether Cipla specifically can win it. Keeping them apart is what stops an attractive but inaccessible space from being recommended.

Read the full answers See the framework


Where the growth actually comes from

Seven of the thirteen points of headline market growth are price rather than demand. The organisers’ glossary is explicit that constant-price MAT measures real demand and quantity confirms it, so reported value growth carries no weight at all in the framework’s future-potential pillar.

Reported growth against real demand


How to read this site

If you want to Read
The answers to the four case questions Case answers
Every metric, weight and formula Prioritisation framework
How the system is put together Architecture
To run it yourself Installation then User guide
To extend it Technical documentation
To challenge a judgement call Assumptions and Limitations
To check it works Evaluation and Testing
The sources Appendix of sources

Verification at a glance

Measure Result
Golden question set 14 of 14 passing
Groundedness 100 per cent
Tool recall 100 per cent
Citation validity 100 per cent
Refusal accuracy 100 per cent
Test suite 150 tests passing
Median answer latency 74 ms

Nothing here is scored by another language model. An LLM-as-judge number is cheap to produce and impossible to defend when a panel asks how the judge was validated, so every measure above is a deterministic assertion against the run.


Deliverables


Back to top

Shreyas Thakur. Built for Ascend Season 4. Figures are computed from the supplied Cardiac prescription audit, MAT February 2026. The dataset itself is licensed material and is not distributed with this site.

This site uses Just the Docs, a documentation theme for Jekyll.